STI571治疗Ph染色体阳性急性髓性白血病  

STI571 Used in Treating Acute Myeloid Leukemia with Philadelphia Chromosome

作　　者：石红霞[1] 江滨[1] 江浩[1] 邱镜莹[1] 刘代红[1] 黄晓军[1] 陆道培[1] 

机构地区：[1]北京大学人民医院血液病研究所

出　　处：《中国实验血液学杂志》2005年第1期88-90,共3页Journal of Experimental Hematology

摘　　要：本研究目的探讨用酪氨酸激酶抑制剂STI5 71治疗Ph染色体阳性急性髓性白血病。 2例Ph染色体阳性急性髓性白血病患者中 1例经常规化疗未获缓解后口服STI5 71治疗 ,另 1例仅接受常规化疗。 2例在缓解后均进行了异基因造血干细胞移植。结果表明 ,1例病人经常规化疗达到血液学缓解 ,另 1例经常规联合化疗未缓解但经STI5 71治疗后达到血液学和遗传学缓解。 2例病人分别于异基因造血干细胞移植后 18天和 11天骨髓恢复造血 ,均未出现严重的移植物抗宿主病。 1例病人在移植后 8个月死于间质性肺炎 ,另 1例现在仍无病存活 5月。结论 :Ph染色体阳性急性髓性白血病预后较差 ,STI5 71可用于治疗此类疾病 ,根治仍须进行造血干细胞移植。The objective was to use STI571, a kind of tyrosine kinase inhibitor, to treat acute myeloid leukemia (AML) with Philadelphia chromosome. 2 AML cases with Philadelphia chromosome, were collected to observe effect of STI571. One of them was given STI571 after routine chemotherapy failed to respond to treatment, other case received routine chemotherapy only. Both of them underwent HLA-matched/mismatched sibling hematopoietic stem cell transplantation (HSCT). The results showed that cytogenetic and hematologic CR was acquired in case 1 with STI571 while another one gained hemotologic CR by accepting routine chemotherapy. Recovery of hemopoiesis was found at 18 and 11 days after HSCT respectively without serious graft-versus-host-diasese. The case 1 has been surviving in disease-free state for 5 months since HSCT. The case 2 died from interrstitial pneumonia at 8 months after HSCT. In conclusion, STI571 is one of choice for the treatment of Philadelphia chromosome positive AML.

关 键 词：STI571 PH染色体 急性髓性白血病 异基因造血干细胞移植 

分 类 号：R733.71[医药卫生—肿瘤] R979.1[医药卫生—临床医学]